684 related articles for article (PubMed ID: 33010985)
1. Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring.
Saad F; Sternberg CN; Efstathiou E; Fizazi K; Modelska K; Lin X; Sugg J; Steinberg J; Noerby B; Shore ND; Hussain M
Eur Urol; 2020 Dec; 78(6):847-853. PubMed ID: 33010985
[TBL] [Abstract][Full Text] [Related]
2. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
Hussain M; Fizazi K; Saad F; Rathenborg P; Shore N; Ferreira U; Ivashchenko P; Demirhan E; Modelska K; Phung D; Krivoshik A; Sternberg CN
N Engl J Med; 2018 Jun; 378(26):2465-2474. PubMed ID: 29949494
[TBL] [Abstract][Full Text] [Related]
3. Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
Altavilla A; Casadei C; Lolli C; Menna C; Ravaglia G; Gurioli G; Farolfi A; Brighi N; Conteduca V; Burgio SL; Schepisi G; Rossi L; Gargiulo S; Lisotti I; De Giorgi U
Expert Opin Pharmacother; 2020 Dec; 21(17):2091-2099. PubMed ID: 32783772
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial.
Tombal B; Saad F; Penson D; Hussain M; Sternberg CN; Morlock R; Ramaswamy K; Ivanescu C; Attard G
Lancet Oncol; 2019 Apr; 20(4):556-569. PubMed ID: 30770294
[TBL] [Abstract][Full Text] [Related]
5. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer.
Denmeade SR; Wang H; Agarwal N; Smith DC; Schweizer MT; Stein MN; Assikis V; Twardowski PW; Flaig TW; Szmulewitz RZ; Holzbeierlein JM; Hauke RJ; Sonpavde G; Garcia JA; Hussain A; Sartor O; Mao S; Cao H; Fu W; Wang T; Abdallah R; Lim SJ; Bolejack V; Paller CJ; Carducci MA; Markowski MC; Eisenberger MA; Antonarakis ES
J Clin Oncol; 2021 Apr; 39(12):1371-1382. PubMed ID: 33617303
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial.
Armstrong AJ; Lin P; Higano CS; Iversen P; Sternberg CN; Tombal B; Phung D; Parli T; Krivoshik A; Beer TM
Eur Urol Oncol; 2019 Nov; 2(6):677-684. PubMed ID: 31274110
[TBL] [Abstract][Full Text] [Related]
7. Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial.
Saad F; de Bono J; Shore N; Fizazi K; Loriot Y; Hirmand M; Franks B; Haas GP; Scher HI
Eur Urol; 2015 Feb; 67(2):223-30. PubMed ID: 25171902
[TBL] [Abstract][Full Text] [Related]
8. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
Sternberg CN; Fizazi K; Saad F; Shore ND; De Giorgi U; Penson DF; Ferreira U; Efstathiou E; Madziarska K; Kolinsky MP; Cubero DIG; Noerby B; Zohren F; Lin X; Modelska K; Sugg J; Steinberg J; Hussain M;
N Engl J Med; 2020 Jun; 382(23):2197-2206. PubMed ID: 32469184
[TBL] [Abstract][Full Text] [Related]
9. Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region.
De Giorgi U; Hussain M; Shore N; Fizazi K; Tombal B; Penson D; Saad F; Efstathiou E; Madziarska K; Steinberg J; Sugg J; Lin X; Shen Q; Sternberg CN
Eur J Cancer; 2021 Dec; 159():237-246. PubMed ID: 34784577
[TBL] [Abstract][Full Text] [Related]
10. Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan.
Yokomizo A; Yonese J; Egawa S; Fukuhara H; Uemura H; Nishimura K; Nagata M; Saito A; Lee T; Yamaguchi S; Nonomura N
Int J Clin Oncol; 2022 Feb; 27(2):418-426. PubMed ID: 34779962
[TBL] [Abstract][Full Text] [Related]
11. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.
Teply BA; Wang H; Luber B; Sullivan R; Rifkind I; Bruns A; Spitz A; DeCarli M; Sinibaldi V; Pratz CF; Lu C; Silberstein JL; Luo J; Schweizer MT; Drake CG; Carducci MA; Paller CJ; Antonarakis ES; Eisenberger MA; Denmeade SR
Lancet Oncol; 2018 Jan; 19(1):76-86. PubMed ID: 29248236
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.
Smith MR; Antonarakis ES; Ryan CJ; Berry WR; Shore ND; Liu G; Alumkal JJ; Higano CS; Chow Maneval E; Bandekar R; de Boer CJ; Yu MK; Rathkopf DE
Eur Urol; 2016 Dec; 70(6):963-970. PubMed ID: 27160947
[TBL] [Abstract][Full Text] [Related]
13. Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL.
Bryce AH; Alumkal JJ; Armstrong A; Higano CS; Iversen P; Sternberg CN; Rathkopf D; Loriot Y; de Bono J; Tombal B; Abhyankar S; Lin P; Krivoshik A; Phung D; Beer TM
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):221-227. PubMed ID: 28117385
[TBL] [Abstract][Full Text] [Related]
14. Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.
Nadal R; Zhang Z; Rahman H; Schweizer MT; Denmeade SR; Paller CJ; Carducci MA; Eisenberger MA; Antonarakis ES
Prostate; 2014 Nov; 74(15):1560-8. PubMed ID: 25176007
[TBL] [Abstract][Full Text] [Related]
15. A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone.
Graff JN; Beer TM; Alumkal JJ; Slottke RE; Redmond WL; Thomas GV; Thompson RF; Wood MA; Koguchi Y; Chen Y; Latour E; Bergan RC; Drake CG; Moran AE
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32616555
[TBL] [Abstract][Full Text] [Related]
16. Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo.
Taplin ME; Armstrong AJ; Lin P; Krivoshik A; Phung D; Parli T; Tombal B; Beer TM
J Urol; 2017 Dec; 198(6):1324-1332. PubMed ID: 28736322
[TBL] [Abstract][Full Text] [Related]
17. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
Penson DF; Armstrong AJ; Concepcion R; Agarwal N; Olsson C; Karsh L; Dunshee C; Wang F; Wu K; Krivoshik A; Phung D; Higano CS
J Clin Oncol; 2016 Jun; 34(18):2098-106. PubMed ID: 26811535
[TBL] [Abstract][Full Text] [Related]
18. Managing Nonmetastatic Castration-resistant Prostate Cancer.
Mateo J; Fizazi K; Gillessen S; Heidenreich A; Perez-Lopez R; Oyen WJG; Shore N; Smith M; Sweeney C; Tombal B; Tomlins SA; de Bono JS
Eur Urol; 2019 Feb; 75(2):285-293. PubMed ID: 30119985
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.
Armstrong AJ; Saad F; Phung D; Dmuchowski C; Shore ND; Fizazi K; Hirmand M; Forer D; Scher HI; Bono J
Cancer; 2017 Jun; 123(12):2303-2311. PubMed ID: 28171710
[TBL] [Abstract][Full Text] [Related]
20. Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial.
Armstrong AJ; Lin P; Tombal B; Saad F; Higano CS; Joshua AM; Parli T; Rosbrook B; van Os S; Beer TM
Eur Urol; 2020 Sep; 78(3):347-357. PubMed ID: 32527692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]